Sugi Predict

Sugi Predict / Targets / CYBB

CYBB

NADPH oxidase 2 · P04839 · CYBB on Sugi Atlas →

8,606 patent compounds predicted against CYBB, 5,756 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1459191 SCHEMBL1459191 1.00 20/20
SCHEMBL1459279 SCHEMBL1459279 1.00 20/20
SCHEMBL1460392 SCHEMBL1460392 1.00 20/20
SCHEMBL1565622 SCHEMBL1565622 1.00 20/20
SCHEMBL1565623 SCHEMBL1565623 1.00 20/20
SCHEMBL1565877 SCHEMBL1565877 1.00 20/20
SCHEMBL1565930 SCHEMBL1565930 1.00 20/20
SCHEMBL1566126 SCHEMBL1566126 1.00 20/20
SCHEMBL1566376 SCHEMBL1566376 1.00 20/20
SCHEMBL1566429 SCHEMBL1566429 1.00 20/20
SCHEMBL1566438 SCHEMBL1566438 1.00 20/20
SCHEMBL1566481 SCHEMBL1566481 1.00 20/20
SCHEMBL1566482 SCHEMBL1566482 1.00 20/20
SCHEMBL1566689 SCHEMBL1566689 1.00 20/20
SCHEMBL1566820 SCHEMBL1566820 1.00 20/20
SCHEMBL1567008 SCHEMBL1567008 1.00 20/20
SCHEMBL1566290 SCHEMBL1566290 0.74 20/20
SCHEMBL2217968 SCHEMBL2217968 0.56 16/20
SCHEMBL2216063 SCHEMBL2216063 0.59 12/20
SCHEMBL2216265 SCHEMBL2216265 0.57 12/20

Clinical trials — most relevant to CYBB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes PHASE4UNKNOWN
Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing. PHASE1/PHASE2COMPLETED
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease PHASE1/PHASE2RECRUITING
Salt-Sensitivity and Immunity Cell Activation PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease PHASE1/PHASE2COMPLETED
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS PHASE2RECRUITING
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Effect of IFN-γ on Innate Immune Cells PHASE1COMPLETED
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers PHASE1COMPLETED
Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up PHASE1COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM PHASE1WITHDRAWN
The Effect of Antioxidants on Skin Blood Flow During Local Heating PHASE1COMPLETED
Endometriosis and Microvascular Dysfunction: Role of Inflammation EARLY_PHASE1RECRUITING
Sex-specific Association With Kidney Disease nanCOMPLETED
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Immunological Profile and Clinical Characteristics of Children Diagnosed With Chronic Granulomatous Disease nanUNKNOWN
Covid-19: Possible Role of Neutrophil Extracellular Traps nanUNKNOWN
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease nanRECRUITING
Lentiviral Gene Therapy for CGD nanRECRUITING
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 nanCOMPLETED
Oxidative Stress and Haemostasis Abnormalities in Cirrhosis nanUNKNOWN
Mucomyst for Hepatitis C nanSUSPENDED
Anti-inflammatory Effects of Fiber nanCOMPLETED
Mechanisms for Individual Differences in Hypertension in Obstructive Sleep nanCOMPLETED
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis nanUNKNOWN
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme nanNOT_YET_RECRUITING
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program) nanCOMPLETED
Flow Mediated Dilation in Association With Hyperuricemia nanUNKNOWN
Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYBB binder may also engage these)

ProteinNameSimilarity
P52649 — 1.000 P52649 →
Q95L74 — 1.000 Q95L74 →
Q61093 — 1.000 Q61093 →
O46522 — 1.000 O46522 →
Q9WV87 — 0.982 Q9WV87 →
Q8CIZ9 — 0.979 Q8CIZ9 →
Q948T9 — 0.978 Q948T9 →
NOX3 NADPH oxidase 3 0.974 landscape →
Q2HXK9 — 0.973 Q2HXK9 →
Q2HXL0 — 0.967 Q2HXL0 →
Q672J9 — 0.967 Q672J9 →
O48538 — 0.967 O48538 →
Q672K1 — 0.966 Q672K1 →
O81210 — 0.965 O81210 →
Q9FIJ0 — 0.964 Q9FIJ0 →
Q948U0 — 0.964 Q948U0 →
Q8R455 — 0.961 Q8R455 →
Q6J2K5 — 0.960 Q6J2K5 →
Q687X5 — 0.959 Q687X5 →
Q5ZAJ0 — 0.959 Q5ZAJ0 →
Q8R4D5 — 0.959 Q8R4D5 →
Q9SW17 — 0.959 Q9SW17 →
Q9SBI0 — 0.958 Q9SBI0 →
NOX5 NADPH oxidase 5 0.957 landscape →
TRPM8 Transient receptor potential cation channel subfamily M member 8 0.957 landscape →
B4G0F3 — 0.955 B4G0F3 →
GLS2 Glutaminase liver isoform, mitochondrial 0.955 landscape →
O81209 — 0.954 O81209 →
Q5R5L9 — 0.954 Q5R5L9 →
Q924Z4 — 0.953 Q924Z4 →